fw-perspective
December 8th, 2016 | News

Vapogenix Secures $8.2 Million in Series C Funding to Advance Innovative Therapy for Wound Pain

HOUSTON, Dec. 08, 2016 (GLOBE NEWSWIRE) — Vapogenix, Inc., a clinical-stage company developing a topical, non-opioid medicine for localized pain, has raised $8.2 million to advance the development of its lead product, a locally-acting analgesic based on volatile anesthetics (VAs), …

digital_horizontal
December 8th, 2016 | News

Houston Biotech Vapogenix Raises $8.2M for Phase 2 Trial

Houston—Vapogenix, a biotech developing a topical non-opioid medication for localized pain, announced Thursday it has raised $8.2 million in a Series C round of funding. The capital will be used for a Phase 2 proof-of-concept study for its drug candidate, …

pehub_logo
December 8th, 2016 | News

Vapogenix Ropes in $8.2M

HOUSTON – December 8, 2016 – Vapogenix, Inc., a clinical-stage company developing a topical, non-opioid medicine for localized pain, has raised $8.2 million to advance the development of its lead product, a locally-acting analgesic based on volatile anesthetics (VAs), the …

nasdaq-apo
December 8th, 2016 | News

Vapogenix Secures $8.2 Million in Series C Funding to Advance Innovative Therapy for Wound Pain

HOUSTON, Dec. 08, 2016 (GLOBE NEWSWIRE) — Vapogenix, Inc., a clinical-stage company developing a topical, non-opioid medicine for localized pain, has raised $8.2 million to advance the development of its lead product, a locally-acting analgesic based on volatile anesthetics (VAs), …

fw-perspective
December 8th, 2016 | News

Vapogenix Secures $8.2 Million in Series C Funding to Advance Innovative Therapy for Wound Pain

HOUSTON, Dec. 08, 2016 (GLOBE NEWSWIRE) — Vapogenix, Inc., a clinical-stage company developing a topical, non-opioid medicine for localized pain, has raised $8.2 million to advance the development of its lead product, a locally-acting analgesic based on volatile anesthetics (VAs), …

digital_horizontal
December 8th, 2016 | News

Houston Biotech Vapogenix Raises $8.2M for Phase 2 Trial

Houston—Vapogenix, a biotech developing a topical non-opioid medication for localized pain, announced Thursday it has raised $8.2 million in a Series C round of funding. The capital will be used for a Phase 2 proof-of-concept study for its drug candidate, …

pehub_logo
December 8th, 2016 | News

Vapogenix Ropes in $8.2M

HOUSTON – December 8, 2016 – Vapogenix, Inc., a clinical-stage company developing a topical, non-opioid medicine for localized pain, has raised $8.2 million to advance the development of its lead product, a locally-acting analgesic based on volatile anesthetics (VAs), the …

nasdaq-apo
December 8th, 2016 | News

Vapogenix Secures $8.2 Million in Series C Funding to Advance Innovative Therapy for Wound Pain

HOUSTON, Dec. 08, 2016 (GLOBE NEWSWIRE) — Vapogenix, Inc., a clinical-stage company developing a topical, non-opioid medicine for localized pain, has raised $8.2 million to advance the development of its lead product, a locally-acting analgesic based on volatile anesthetics (VAs), …